Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

被引:19
作者
Song, Jehun [1 ]
Kang, Seongmin [1 ]
Choi, Seung Won [1 ]
Seo, Kwang Won [2 ]
Lee, Sunggun [3 ]
So, Min Wook [4 ]
Lim, Doo-Ho [1 ]
机构
[1] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Rheumatol,Dept Internal Med, 877 Bangeojinsunhwan Doro, Ulsan 44033, South Korea
[2] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Ulsan, South Korea
[3] Inje Univ, Haeundae Paik Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Busan, South Korea
[4] Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Rheumatol, Yangsan, South Korea
关键词
Coronavirus; COVID-19; Pneumonia; Rheumatoid arthritis; Disease-modifying antirheumatic drugs; INFECTIONS;
D O I
10.1007/s00296-020-04584-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [31] Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
    van Riel, PLCM
    Haagsma, CJ
    Furst, DE
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 1999, 13 (04): : 689 - 700
  • [32] The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Otani, Hiroshi
    Abe, Asami
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    INTERNAL MEDICINE, 2023, 62 (03) : 373 - 379
  • [33] Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer
    Kleinert, S.
    Waldner, M.
    Wendler, J.
    Kunzmann, V.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (01): : 41 - 46
  • [34] Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy
    Intongkam, Samanan
    Samakarnthai, Parinya
    Pakchotanon, Rattapol
    Narongroeknawin, Pongthorn
    Assavatanabodee, Paijit
    Chaiamnuay, Sumapa
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 (08) : 329 - 334
  • [35] Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs
    Mori, Shunsuke
    MODERN RHEUMATOLOGY, 2011, 21 (06) : 621 - 627
  • [36] Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
    Durand, Caylib
    Eldoma, Maysoon
    Marshall, Deborah A.
    Bansback, Nick
    Hazlewood, Glen S.
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (02) : 176 - 187
  • [37] Coronavirus Disease 19 (COVID-19) complicated with post-viral arthritis
    Fragata, I
    Mourao, A. F.
    ACTA REUMATOLOGICA PORTUGUESA, 2020, 45 (04): : 278 - 280
  • [38] Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics
    Osiri, Manathip
    Wongpiyabovorn, Jongkonnee
    Sattayasomboon, Youwanuch
    Thammacharoenrach, Niramol
    CLINICAL RHEUMATOLOGY, 2016, 35 (07) : 1673 - 1681
  • [39] Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics
    Manathip Osiri
    Jongkonnee Wongpiyabovorn
    Youwanuch Sattayasomboon
    Niramol Thammacharoenrach
    Clinical Rheumatology, 2016, 35 : 1673 - 1681
  • [40] Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis
    Wu, C. -Y.
    Xiong, L. Y.
    Wong, Y. Y.
    Noor, S.
    Bradley-Ridout, G.
    Swardfager, Walter
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2024, 11 (05): : 1339 - 1347